Voyager Therapeutics, Inc. Common Stock VYGR
i
Market dataready · fetched 2026-11-07T01:27:41.133Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T22:24:26.667495089Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-07T01:27:40.220050+00:00
Voyager Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.20 | 711.8% | 67.4% | |||
| 25Δ | 3.32 | 656.0% | 60.6% | |||
| 30Δ | 3.45 | 600.3% | 53.8% | |||
| 35Δ | 3.57 | 544.5% | 47.0% | |||
| 40Δ | 3.95 | 302.4% | 134.0% | 3.69 | 488.8% | 40.2% |
| 45Δ | 3.80 | 336.5% | 131.5% | 3.82 | 433.1% | 33.4% |
| 50Δ | 3.66 | 370.5% | 128.9% | 3.94 | 377.3% | 26.6% |
| 55Δ | 3.52 | 404.6% | 126.4% | 4.09 | 340.3% | 21.7% |
| 60Δ | 3.37 | 438.6% | 123.9% | 4.26 | 319.5% | 18.4% |
| 65Δ | 3.23 | 472.7% | 121.3% | 4.44 | 298.7% | 15.1% |
| 70Δ | 3.09 | 506.7% | 118.8% | 4.61 | 277.9% | 11.9% |
| 75Δ | 4.78 | 257.0% | 8.6% | |||
| 80Δ | 4.95 | 236.2% | 5.3% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.20
- IV
- 711.8%
- B/E move
- 67.4%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.32
- IV
- 656.0%
- B/E move
- 60.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.45
- IV
- 600.3%
- B/E move
- 53.8%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.57
- IV
- 544.5%
- B/E move
- 47.0%
40Δ
- Pseudo strike
- 3.95
- IV
- 302.4%
- B/E move
- 134.0%
- Pseudo strike
- 3.69
- IV
- 488.8%
- B/E move
- 40.2%
45Δ
- Pseudo strike
- 3.80
- IV
- 336.5%
- B/E move
- 131.5%
- Pseudo strike
- 3.82
- IV
- 433.1%
- B/E move
- 33.4%
50Δ
- Pseudo strike
- 3.66
- IV
- 370.5%
- B/E move
- 128.9%
- Pseudo strike
- 3.94
- IV
- 377.3%
- B/E move
- 26.6%
55Δ
- Pseudo strike
- 3.52
- IV
- 404.6%
- B/E move
- 126.4%
- Pseudo strike
- 4.09
- IV
- 340.3%
- B/E move
- 21.7%
60Δ
- Pseudo strike
- 3.37
- IV
- 438.6%
- B/E move
- 123.9%
- Pseudo strike
- 4.26
- IV
- 319.5%
- B/E move
- 18.4%
65Δ
- Pseudo strike
- 3.23
- IV
- 472.7%
- B/E move
- 121.3%
- Pseudo strike
- 4.44
- IV
- 298.7%
- B/E move
- 15.1%
70Δ
- Pseudo strike
- 3.09
- IV
- 506.7%
- B/E move
- 118.8%
- Pseudo strike
- 4.61
- IV
- 277.9%
- B/E move
- 11.9%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.78
- IV
- 257.0%
- B/E move
- 8.6%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.95
- IV
- 236.2%
- B/E move
- 5.3%
Options history
No recorded observations
Biotechnology
WHWK
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. The company is headquartered in…
More →WVE
Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes and produces new stereopure oligonucleotides through PRISM, a drug discovery and development…
More →XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases. The company is headquartered in…
More →XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company…
More →XFOR
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back…
More →XNCR
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients…
More →